医学
肿瘤科
突变
内科学
癌症研究
遗传学
基因
生物
作者
J.C-H. Yang,M. Wang,C-H. Chiu,Pei-Wen Hsu,Paul Mitchell,Chin-Chih Chang,T.M. Kim,Thomas John,L. Greillier,Lyudmila Bazhenova,Enric Carcereny,Alexander I. Spira,Byoung Yong Shim,K.H. Lee,M. Cobo Dols,F. Ghiringhelli,Chi Wai Yip,Jie Xiong,Pasi A. Jänne,C. Zhou
标识
DOI:10.1016/j.annonc.2023.09.2358
摘要
Sunvozertinib (DZD9008) is a rationally designed, irreversible EGFR inhibitor targeting EGFR mutations with wild-type EGFR selectivity. Primary analysis of two ongoing pivotal studies (WU-KONG1 [NCT03974022] and WU-KONG6 [NCT05712902 & CTR20211009]) have demonstrated promising efficacy and safety of sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion mutations (exon20ins) in ≥ 2nd line settings. Herein, we reported preliminary results of sunvozertinib in treatment naïve EGFR exon20ins NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI